1 Fortis MEDCENTRE

(A unit of Fortis Hospital Mobile)

SCO 11, Sector 11-D, Chandigach - 1600 1

ma Ramush Chang

12385677


Date: 29-1-2014

54year Age

Gender: mail

Nursing Assessment

	Profile
Height (cm) 169 cm	Wast Eincumference (cm) 36 ischy
Weight (Kg.): 69 (cg	Body Mass Index 24 4 4 kg/mc
Occupation:	Mantai Status 🗀 Single Warried
Vit	al Signs
Pulse Rate Umin 626/ms	Respiratory Rate (/min) 263/min
Blood Pressure (minimum 1301 75 mm/g	Temperature (if Tebrile) 4 debrily
	t History
Hypertension Since dyean	[Quapetes 1
Heart disease	[4 Institutema .
φ Asthma	* [* _ therrolesis
to Allergres :	
For	Women
LMP: E	Last Pap smear done in
Menopause [] tres with	Last Marnmography done in
Consent for X-ray & Martinography	
Current	Viedications



CHANDIGARH (A unit of Fortis Hospital Mohali) SCO 11, Sector 11-D, Chandigarh - 150011

MR Ramesh chand

UHID

12385677

Date 29-2-204

Age


54you


Gender: male

Internal Medicine Consultation

Relevant History:

Diagnosis





CHANDIGARH
(A unit of Forth Holpital Mobili)
SCO 11. Sector 11-D. Chandigarh - 160011

vame one Ramesh Chand

UHID : 14385677 Date

Date: 29-2-2029

Age: 54yr Gender: Mal

Ophthalmology Consultation

History: HT for 2 year on Pyp

Examination findings:

Visual acuity < R

Visual acuity with glasses

6/6

Celour Vision (

E WAL

Slit Lamp Examination


RE

clean

6

Europus Examination

RE



(0

Diagnosis: Peul byolia BÉ

Treatment"

Spectacle prescription:

Right eyes

Distance

aided 56

Left eve

Distance

reded AXIS VA

Signature and strung of the Dobthalroologist

sh , Chand 2385677	Maje	X & 8 5	29.02.2024 10:08:07 Fortis Med Centre sector 11 Chandgarh	2:08:02		Order A Ind Medic	Location: Order Number: Visit: Indication: Medication 1:	S S S S S S S S S S S S S S S S S S S	65 bpm	md gHmi
	Technician: Ordering Ph: Referring Ph: Attending Ph:					P P P P P P P P P P P P P P P P P P P	Medication 2: Medication 3:			
	QRS: QT/QTcBaz: PR: P/QRS/T:	76 ms 392 / 407 ms 206 ms 86 ms 918 / 923 ms 55 / 76 / 61 degrees		Normal sinus rhythm						
{	{	1	\right\{\frac{1}{2}}	1	5	\{\bar{\}}	F	{		}
	}	<u> </u>	3	\ \ \	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	4	4	. <		ل ا
al.	}	}	\begin{align*} \frac{1}{2}	}	EW T		-\{			
avr }			Į	}	3	\ -_	7	7		
awr	ļ	}	ļ		2 2	\ \{	4	4		ڵ
ave	}		3	3	*\	_{		4		٦
	}		3	3	}	\frac{1}{2}	3	3	3	J
9	GE MAC2000	12SL™ v241		25 mm/s	10 mm/mV	ABS	0.56-20 Hz	20 Hz	Unconfirmed 2x5x6_25_R1	T.



Fortis Medcentre

SCO-11, Sector-11-D, Chandigarh - 160 011 (India)

Telephone ; 0172 506 1222 / 505 5441

: 0172-5055440

E-mail : contactus.fmc@fortishealthcare.com

Website : www.fortishealthcare.com

DEPARTMENT OF FMC-RADIOLOGY LAB

Date: 29/Feb/2024

Name: Mr. Ramesh Chand Age | Sex: 54 YEAR(S) | Male

Order Station : FRONTOFFICE-FMC

Bed Name:

UHID | Episode No : 12385677 | 2630/24/10021

Order No | Order Date: 10021/PN/OP/2402/6710 | 29-Feb-2024

Admitted On | Reporting Date : 29-Feb-2024 10:46:36

Order Doctor Name: Dr.SELF.

CHEST X-RAY (PA VIEW)

Unfolding arch of aorta.

Both the domes of diaphragm are normal.

Both costophrenic angles are normal.

Both lung fields are clear.

Cardiac size and silhouette are normal.

Both hila and mediastinum are normal.

Bony cage and soft tissues are normal.

Please correlate clinically and with other relevant investigations.

Dr. ADITI PANWAR

PMC - 41230

Consultant Radiologist



CHANDIGARH

Fortis Medcentre

SCO-11, Sector-11-D, Chandigarh - 160 011 (India)

Telephone | 0172 506 1222 / 505 5441

Fax : 0172-5055440

E-mail : contactus.fmc@fortishealthcare.com

Website : www.fortishealthcare.com

NAME: MR. RAMESH CHAND

AGE AND SEX: 54Y/M UHID NO: 12385677 DATE:29/02/2024

ROI: WHOLE ABDOMEN

Liver is normal in size, outline and echogenicity. No focal lesion seen. IHBR's are not dilated. Portal vein and hepatic veins are normal.

Gall bladder is normally distended with anechoic lumen. Wall thickness is normal. No calculus / focal lesion seen. No pericholecystic fluid / collection seen. CBD is normal.

Pancreas is visualized in region of head and proximal body and is normal in size, shape, outline and echotexture. No focal lesion seen. Distal body and tail are obscured by bowel gases.

Spleen is normal in size, outline and echotexture. No focal lesion seen.

Right kidney is normal in size, outline and echogenicity. Cortico-medullary differentiation is maintained. No hydronephrosis / calculus is seen.

Left kidney is normal in size, outline and echogenicity. Cortico-medullary differentiation is maintained. No hydronephrosis / calculus is seen.

Retroperitoneum is normal.

The urinary bladder is fully distended and is normal in outline and wall thickness. No calculi or growth seen. PVRU is insignificant.

Prostate is enlarged (25.8 cc) in size and shows normal outline and echo pattern. No focal lesion seen.

No free fluid is seen.

Opinion: Prostatomegaly Grade I

Suggested clinical correlation.

Dr. ADITI PANWAR PMC - 41230 Consultant Radiologist RAMESH CHAND 54 M

Accession #:

Study Date: 29/02/2024

Patient ID: 12385677

Alt ID:

DOB:

Age:

Gender: M Ht:

Wt:

BSA:

Institution: Fortis MEDCENTRE, Chandigarh

Referring Physician:

Physician of Record:

Performed By:

Comments:

Abdominal: Measurements and Calculations

2D Abdominal Organs and Vessels

PV Bladder Vol

34.91 ml

PV Bladder H

2.20 cm

PV Bladder L

5.93 cm

PV Bladder W

5.11 cm

Other Measurements

Abdomen General: Bladder Dimensions

PROST L

3.36 cm

PROST H

4.05 cm

PROST W

3.62 cm

Images



Signature

Signature:

Name(Print):

Date:

-Physician SCO 11, Sector 11 D Chandigarh

Station Telephone:

EXERCISE STRESS TEST REPORT

Patient Name: Chand, Ramesh Patient ID: 12385677 Height: 168 cm

DOB: 31,03,1969 Age: 54yrs Gender: Male Race: Indian

Study Date: 29.02.2024

Test Type: --Protocol: BRUCE

Weight: 69 kg

Referring Physician: --

Attending Physician: DR MANJEET/DR VIJAY HARJAI

Medications:

77

Medical History:

--

Reason for Exercise Test:

Exercise Test Summary

Phase Name	Stage Name	Time in Stage	Speed (km/h)	Grade (%)	HR (bpm)	BP (mmHg)	Comment
PRETEST	SUPINE	00:03	0.00	0.00	101		
	HYPERV. WARM-UP	00:03 02:15	0.00 1.60	0.00	101		
EXERCISE	STAGE 1	03:00	2.70	0.00	107	130/75	
	STAGE 2	03:00	4.00	12.00	108	130/75	
	STAGE 3 STAGE 4	03:00	5.50 6.80	14.00 16.00	117	140/75	
RECOVERY		04:20	0.00	6,20	107	130/75	

The patient exercised according to the BRUCE for 9:34 min:s, achieving a work level of Max. METS: 12.00. The resting heart rate of 101 bpm rose to a maximal heart rate of 126 bpm. This value represents 75 % of the maximal, age-predicted heart rate. The resting blood pressure of 130/75 mmHg, rose to a maximum blood pressure of 140/75 mmHg. The exercise test was stopped due to Target heart rate achieved.

Interpretation

Summary: Resting ECG: see 12SL interpretation.

Functional Capacity: normal.

HR Response to Exercise: attenuated secondary to medication.


BP Response to Exercise: normal resting BP - exaggerated response, normal resting BP - appropriate response.


Arrhythmias: none.


Conclusions


--


Physician



























CODE/NAME & ADDRESS : C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817 ACCESSION NO: 0006XB029400

PATIENT ID : FH.12385677 CLIENT PATIENT ID: UID:12385677

ABHA NO :

O AGE/SEX : 54 Years Male DRAWN : 29/02/2024 10:20:00

RECEIVED : 29/02/2024 14:37:14 REPORTED : 04/03/2024 11:25:55

CLINICAL INFORMATION:

UID:12385677 REQNO-1669336

CORP-OPD

BILLNO-10021240PCS003255 BILLNO-10021240PCS003255

Test Report Status <u>Final</u> Results Biological Reference Interval Units

HAEMATOLOGY - CBC						
CBC-5, EDTA WHOLE BLOOD						
BLOOD COUNTS, EDTA WHOLE BLOOD						
HEMOGLOBIN (HB) METHOD: SLS- HEMOGLOBIN DETECTION METHOD	15.1	13.0 - 17.0	g/dL			
RED BLOOD CELL (RBC) COUNT METHOD: HYDRODYNAMIC FOCUSING	4.67	4.5 - 5.5	mil/µL			
WHITE BLOOD CELL (WBC) COUNT METHOD: FLOWCYTOMETRY	9.31	4.0 - 10.0	thou/µL			
PLATELET COUNT METHOD: HYDRO DYNAMIC FOCUSING METHOD / MICROSCOPY	268	150 - 410	thou/µL			
RBC AND PLATELET INDICES						
HEMATOCRIT (PCV)	48.7	40.0 - 50.0	%			
METHOD: HYDRODYNAMIC FOCUSING	40.7	40.0 30.0	70			
MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED PARAMETER	104.3 High	83.0 - 101.0	fL			
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED PARAMETER	32.3 High	27.0 - 32.0	pg			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION(MCHC)	31.0 Low	31.5 - 34.5	g/dL			
METHOD : CALCULATED PARAMETER	440 111 1		0.4			
RED CELL DISTRIBUTION WIDTH (RDW)	14.3 High	11.6 - 14.0	%			
METHOD: CALCULATED PARAMETER MENTZER INDEX	22.3					
METHOD : CALCULATED PARAMETER	22.3					
MEAN PLATELET VOLUME (MPV)	10.0	6.8 - 10.9	fL			
METHOD : CALCULATED PARAMETER		0.0 10.0				

Subhijit Kaul

Dr. Subhijit kaur (MD, Pathology) Senior Resident, 49300 Shapour

Dr. Shafira Garg (MD, Pathology) Attending Consultant,47150 Inset.

Dr. Irneet Mundi (MD,DNB Pathology) Associate Consultant, 34080





Page 1 Of 21

View Details

View Report

PERFORMED AT:

CLINICAL LABORATORY
Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Mohali, 160062 Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN - L85110DL1996PLC076704







CODE/NAME & ADDRESS : C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XB029400 PATIENT ID : FH.12385677

CLIENT PATIENT ID: UID:12385677

ABHA NO

AGE/SEX :54 Years Male :29/02/2024 10:20:00 DRAWN RECEIVED: 29/02/2024 14:37:14

REPORTED: 04/03/2024 11:25:55

CLINICAL INFORMATION:

UID:12385677 REQNO-1669336

CORP-OPD

BILLNO-1002124OPCS003255 BILLNO-10021240PCS003255

BILLINO-10021240PC3	5003233			
Test Report Status	<u>Final</u>	Results	Biological Reference	Interval Units
WBC DIFFERENTIAL	. COUNT			
NEUTROPHILS		58	40.0 - 80.0	%
METHOD : FLOW CYTOMETR	RY+LEISHMAIN STAIN+MICROSCOPY			
LYMPHOCYTES		24	20.0 - 40.0	%
METHOD: FLOW CYTOMETR	RY+LEISHMAIN STAIN+MICROSCOPY			
MONOCYTES		12 High	2.0 - 10.0	%
METHOD : FLOW CYTOMETR	RY+LEISHMAIN STAIN+MICROSCOPY			
EOSINOPHILS		6	1 - 6	%
METHOD: FLOW CYTOMETR	RY+LEISHMAIN STAIN+MICROSCOPY			
BASOPHILS		00	0 - 2	%
	RY+LEISHMAIN STAIN+MICROSCOPY			
ABSOLUTE NEUTRO		5.40	2.0 - 7.0	thou/µL
METHOD : CALCULATED PAR				
ABSOLUTE LYMPHO		2.23	1.0 - 3.0	thou/µL
METHOD : CALCULATED PAR		4.45 111 1	0.2.4.0	
ABSOLUTE MONOCY		1.12 High	0.2 - 1.0	thou/µL
METHOD : CALCULATED PAR		O EG Ulah	0.02.0.50	thou/ul
ABSOLUTE EOSINO		0.56 High	0.02 - 0.50	thou/µL
METHOD : CALCULATED PAR		2.4		
NEU IKOPHIL LYMPI	HOCYTE RATIO (NLR)	2.4		

METHOD: CALCULATED PARAMETER

Interpretation(s)
RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(413) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR =

3.3, COVID-19 patients tend to show mild disease.
(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Subhijit kaur (MD, Pathology) Senior Resident, 49300

Dr. Shafira Garg (MD, Pathology) Attending Consultant, 47150

Dr. Irneet Mundi (MD,DNB Pathology) Associate Consultant, 34080





Page 2 Of 21

View Report

PERFORMED AT:

Subhijit Kow

CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Mohali, 160062 Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -

Email: lab.mohali@fortishealthcare.com



L85110DL1996PLC076704





CODE/NAME & ADDRESS : C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817 ACCESSION NO: 0006XB029400

PATIENT ID : FH.12385677 CLIENT PATIENT ID: UID:12385677

ABHA NO :

AGE/SEX : 54 Years Male
DRAWN : 29/02/2024 10:20:00

RECEIVED : 29/02/2024 14:37:14 REPORTED : 04/03/2024 11:25:55

CLINICAL INFORMATION:

UID:12385677 REQNO-1669336

CORP-OPD

BILLNO-10021240PCS003255 BILLNO-10021240PCS003255

Test Report Status <u>Final</u> Results Biological Reference Interval Units

HAEMATOLOGY

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD

E.S.R 05 0 - 14 mm at 1 hr

METHOD: WESTERGREN METHOD

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C 5.7 Non-diabetic: < 5.7 %

Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested: > 8.0

(ADA Guideline 2021)

METHOD: HPLC

ESTIMATED AVERAGE GLUCOSE(EAG) 116.9 High < 116.0 mg/dL

METHOD: CALCULATED PARAMETER

Subhijit Kowl

Dr. Subhijit kaur (MD, Pathology) Senior Resident, 49300 Shafia

Dr. Shafira Garg (MD, Pathology) Attending Consultant,47150 geneat.

Dr. Irneet Mundi (MD,DNB Pathology) Associate Consultant, 34080





View Details





Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -

Email: lab.mohali@fortishealthcare.com



L85110DL1996PLC076704

Page 3 Of 21





CODE/NAME & ADDRESS: C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XB029400

PATIENT ID : FH.12385677 CLIENT PATIENT ID: UID:12385677

ABHA NO

AGE/SEX : 54 Years Male DRAWN :29/02/2024 10:20:00

RECEIVED: 29/02/2024 14:37:14 REPORTED: 04/03/2024 11:25:55

CLINICAL INFORMATION:

UID:12385677 REQNO-1669336

CORP-OPD

BILLNO-1002124OPCS003255 BILLNO-1002124OPCS003255


Test Report Status

<u>Final</u>

Results

Biological Reference Interval

Units



ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD-**TEST DESCRIPTION**:Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

REFERENCE:

Subhijit Kow

Dr. Subhijit kaur (MD, Pathology) Senior Resident, 49300

Dr. Shafira Garg (MD, Pathology) Attending Consultant, 47150

Dr. Irneet Mundi (MD,DNB Pathology) Associate Consultant, 34080





Page 4 Of 21

View Report

PERFORMED AT:

CLINICAL LABORATORY

Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Mohali, 160062 Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -L85110DL1996PLC076704







Units

PATIENT NAME: RAMESH CHAND REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XB029400

PATIENT ID : FH.12385677 CLIENT PATIENT ID: UID:12385677

ABHA NO

AGE/SEX : 54 Years Male :29/02/2024 10:20:00 DRAWN

RECEIVED: 29/02/2024 14:37:14 REPORTED: 04/03/2024 11:25:55

CLINICAL INFORMATION:

UID:12385677 REQNO-1669336

CORP-OPD

BILLNO-1002124OPCS003255 BILLNO-1002124OPCS003255

Test Report Status Results **Biological Reference Interval** <u>Final</u>

- 1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

 GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:
- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.
- 3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
- 2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
- 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
 c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Subhijit Koul

Dr. Subhijit kaur (MD, Pathology) Senior Resident, 49300

Dr. Shafira Garg (MD, Pathology) Attending Consultant, 47150

Dr. Irneet Mundi (MD,DNB Pathology) Associate Consultant, 34080





Page 5 Of 21

View Report

PERFORMED AT:

CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Punjab, India

L85110DL1996PLC076704

Email: lab.mohali@fortishealthcare.com



Mohali, 160062

Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -





CODE/NAME & ADDRESS : C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817 ACCESSION NO: 0006XB029400

PATIENT ID: FH.12385677
CLIENT PATIENT ID: UID:12385677

ABHA NO :

AGE/SEX : 54 Years Male DRAWN : 29/02/2024 10:20:00

> RECEIVED : 29/02/2024 14:37:14 REPORTED : 04/03/2024 11:25:55

CLINICAL INFORMATION:

UID:12385677 REQNO-1669336

CORP-OPD

BILLNO-10021240PCS003255 BILLNO-10021240PCS003255

Test Report Status Final Results Biological Reference Interval Units

	BIOCHEMISTRY		
LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL METHOD: DIAZONIUM ION, BLANKED (ROCHE)	0.75	UPTO 1.2	mg/dL
BILIRUBIN, DIRECT METHOD: DIAZOTIZATION	0.19	0.00 - 0.30	mg/dL
BILIRUBIN, INDIRECT METHOD: CALCULATED PARAMETER	0.56	0.00 - 0.60	mg/dL
TOTAL PROTEIN METHOD: BIURET	7.2	6.6 - 8.7	g/dL
ALBUMIN METHOD: BROMOCRESOL GREEN	4.5	3.97 - 4.94	g/dL
GLOBULIN	2.7	2.0 - 4.0 Neonates - Pre Mature: 0.29 - 1.04	g/dL
METHOD: CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO METHOD: CALCULATED PARAMETER	1.7	1.0 - 2.0	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	22	0 - 40	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: UV WITHOUT PYRIDOXAL-5 PHOSPHATE	14	0 - 41	U/L
ALKALINE PHOSPHATASE METHOD: PNPP - AMP BUFFER	70	40 - 129	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: GAMMA GLUTAMYLCARBOXY 4NITROANILIDE	23	8 - 61	U/L
LACTATE DEHYDROGENASE METHOD: LACTATE -PYRUVATE UV	178	135 - 225	U/L

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 91 74 - 106 mg/dL

Ritu Pantay

Dr. Ritu Pankaj (MD,Pathology), PDCC Additional Director, 30897 Ms. Hardeep Kaur, M.Sc. Biochemistry Meenahah: Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant,48159





Page 6 Of 21

View Details

View Report



CLINICAL LABORATORY
Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Mohali, 160062 Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -

L85110DL1996PLC076704 Email: lab.mohali@fortishealthcare.com







CODE/NAME & ADDRESS : C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817 ACCESSION NO: **0006XB029400**PATIENT ID : FH.12385677

CLIENT PATIENT ID: UID:12385677 ABHA NO : AGE/SEX : 54 Years Male DRAWN : 29/02/2024 10:20:00 RECEIVED : 29/02/2024 14:37:14

REPORTED :04/03/2024 11:25:55

CLINICAL INFORMATION:

UID:12385677 REQNO-1669336

CORP-OPD

BILLNO-10021240PCS003255 BILLNO-10021240PCS003255


Test Report Status

<u>Final</u>

Results

Biological Reference Interval Units

METHOD: HEXOKINASE



BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN

METHOD: UREASE - UV

9

6 - 20

mg/dL

Ritu Pantay

Dr. Ritu Pankaj (MD,Pathology), PDCC

Additional Director, 30897

Hony

Ms. Hardeep Kaur, M.Sc. Biochemistry Meenahahi Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant,48159





Page 7 Of 21

View Details

View Repor



CLINICAL LABORATORY
Fortis Heart Institute & Multispeciality Hospital, Sector 62,Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -

L85110DL1996PLC076704







CODE/NAME & ADDRESS : C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XB029400 PATIENT ID : FH.12385677

CLIENT PATIENT ID: UID:12385677

ABHA NO

AGE/SEX : 54 Years Male :29/02/2024 10:20:00 DRAWN RECEIVED: 29/02/2024 14:37:14

REPORTED :04/03/2024 11:25:55


CLINICAL INFORMATION:

UID:12385677 REQNO-1669336

CORP-OPD

BILLNO-1002124OPCS003255 BILLNO-1002124OPCS003255

Test Report Status Results Biological Reference Interval Units <u>Final</u>



URIC ACID, SERUM

URIC ACID 6.5 3.4 - 7.0mg/dL

METHOD: URICASE, COLORIMETRIC

CREATININE EGFR

CREATININE 0.70 0.70 - 1.20mg/dL

METHOD: ALKALINE PICRATE-KINETIC

54 **AGE** years



Dr. Ritu Pankaj (MD, Pathology), **PDCC**

Additional Director, 30897

Ms. Hardeep Kaur, M.Sc. **Biochemistry**

Meenahahi Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159





Page 8 Of 21



Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -L85110DL1996PLC076704





CODE/NAME & ADDRESS : C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XB029400 PATIENT ID : FH.12385677

CLIENT PATIENT ID: UID:12385677

ABHA NO

AGE/SEX : 54 Years Male :29/02/2024 10:20:00 DRAWN RECEIVED: 29/02/2024 14:37:14 REPORTED :04/03/2024 11:25:55

CLINICAL INFORMATION:

UID:12385677 REQNO-1669336

CORP-OPD


BILLNO-1002124OPCS003255 BILLNO-1002124OPCS003255

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units

GLOMERULAR FILTRATION RATE (MALE)

109

GFR of +90normal or minimal kidney damage with normal GFR 89-60 mild decrease 59-30 moderate decrease 29-15 severe decrease < 15 kidney failure (units: mL/min/1.73mSq.)



Interpretation(s)

Ritu Pantay

Dr. Ritu Pankaj (MD, Pathology), **PDCC** Additional Director, 30897

Ms. Hardeep Kaur, M.Sc. **Biochemistry**

Meenahah: Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159





Page 9 Of 21

View Report



CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Email: lab.mohali@fortishealthcare.com

Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -L85110DL1996PLC076704







CODE/NAME & ADDRESS: C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XB029400

PATIENT ID : FH.12385677 CLIENT PATIENT ID: UID:12385677

ABHA NO

AGE/SEX : 54 Years Male DRAWN :29/02/2024 10:20:00

RECEIVED: 29/02/2024 14:37:14 REPORTED: 04/03/2024 11:25:55

CLINICAL INFORMATION:

UID:12385677 REQNO-1669336

CORP-OPD

BILLNO-1002124OPCS003255 BILLNO-1002124OPCS003255

GLUCOSE POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)


82

Non-Diabetes

mg/dL

70 - 140

METHOD: HEXOKINASE



Interpretation(s)
LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemolytic anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT

Ritu Pantay

Dr. Ritu Pankaj (MD, Pathology), **PDCC** Additional Director, 30897

Ms. Hardeep Kaur, M.Sc. **Biochemistry**

Meenahahi Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159





View Report



CLINICAL LABORATORY

Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -

Email: lab.mohali@fortishealthcare.com



L85110DL1996PLC076704





CODE/NAME & ADDRESS: C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XB029400

PATIENT ID : FH.12385677 CLIENT PATIENT ID: UID:12385677 AGE/SEX : 54 Years Male DRAWN :29/02/2024 10:20:00 RECEIVED: 29/02/2024 14:37:14

REPORTED: 04/03/2024 11:25:55

CLINICAL INFORMATION:

UID:12385677 REQNO-1669336

CORP-OPD

BILLNO-1002124OPCS003255 BILLNO-1002124OPCS003255

Test Report Status Results **Biological Reference Interval** Units Final

ABHA NO

is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease,Rickets,Sarcoidosis etc. Lower-than-normal ALP levels seen

in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease. **GGT** is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

GLUCOSE FASTING FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease,

malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol;sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values),there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels-Low Zinc intake,OCP,Multiple Sclerosis GLUCOSE POST-PRANDIAL, PLASMA-Spectrophotometry Hexokinase

Ritu Pantay

Dr. Ritu Pankaj (MD, Pathology), **PDCC** Additional Director, 30897

Ms. Hardeep Kaur, M.Sc. **Biochemistry**

Meenahahi Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159





Page 11 Of 21

View Report



Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -

L85110DL1996PLC076704 Email: lab.mohali@fortishealthcare.com





Punjab, India





CODE/NAME & ADDRESS : C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XB029400

PATIENT ID : FH.12385677 CLIENT PATIENT ID: UID:12385677

ABHA NO

AGE/SEX : 54 Years Male :29/02/2024 10:20:00 DRAWN RECEIVED: 29/02/2024 14:37:14

REPORTED :04/03/2024 11:25:55

CLINICAL INFORMATION:

LIPID PROFILE, SERUM

UID:12385677 REQNO-1669336

CORP-OPD

BILLNO-1002124OPCS003255 BILLNO-1002124OPCS003255

Test Report Status Results **Biological Reference Interval** Units **Final**

BIOCHEMISTRY - LIPID

215 High CHOLESTEROL, TOTAL < 200 Desirable mg/dL 200 - 239 Borderline High >/= 240 High METHOD: CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE TRIGLYCERIDES 138 < 150 Normal mg/dL 150 - 199 Borderline High 200 - 499 High >/= 500 Very High METHOD: ENZYMATIC ASSAY 42 < 40 Low HDL CHOLESTEROL mg/dL >/=60 High METHOD: DIRECT MEASURE - PEG 168 High LDL CHOLESTEROL, DIRECT < 100 Optimal mg/dL 100 - 129 Near or above optimal 130 - 160 Borderline High 161 - 189 High >/= 190 Very High METHOD: CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE 173 High NON HDL CHOLESTEROL mg/dL Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189

27.6

5.1 High

Ms. Hardeep Kaur, M.Sc. **Biochemistry**

Meenahah Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159

Ritu Pantay

Dr. Ritu Pankaj (MD, Pathology), Additional Director, 30897

High: 190 - 219 Very high: > or = 220

Desirable value:

3.3-4.4 Low Risk 4.5-7.0 Average Risk 7.1-11.0 Moderate Risk > 11.0 High Risk

10 - 35





Page 12 Of 21

PERFORMED AT:

CLINICAL LABORATORY

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -

Email: lab.mohali@fortishealthcare.com



mg/dL

Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

L85110DL1996PLC076704

VERY LOW DENSITY LIPOPROTEIN

METHOD: CALCULATED PARAMETER

CHOL/HDL RATIO





CODE/NAME & ADDRESS : C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XB029400 PATIENT ID : FH.12385677 CLIENT PATIENT ID: UID:12385677

ABHA NO

AGE/SEX : 54 Years Male :29/02/2024 10:20:00 DRAWN

RECEIVED: 29/02/2024 14:37:14 REPORTED :04/03/2024 11:25:55

CLINICAL INFORMATION:

UID:12385677 REQNO-1669336

CORP-OPD

BILLNO-1002124OPCS003255 BILLNO-1002124OPCS003255

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units
	<u></u>			


LDL/HDL RATIO 4.0 High 0.5 - 3.0 Desirable/Low Risk

3.1 - 6.0 Borderline/Moderate

Risk

>6.0 High Risk

METHOD: CALCULATED PARAMETER



Ms. Hardeep Kaur, M.Sc. **Biochemistry**

Meenaheh: Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159

Ritu Pantay

Dr. Ritu Pankaj (MD, Pathology), **PDCC** Additional Director, 30897





Page 13 Of 21



CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -

Email: lab.mohali@fortishealthcare.com



L85110DL1996PLC076704





CODE/NAME & ADDRESS : C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XB029400 PATIENT ID : FH.12385677

CLIENT PATIENT ID: UID:12385677 ABHA NO

AGE/SEX : 54 Years Male :29/02/2024 10:20:00 DRAWN

RECEIVED: 29/02/2024 14:37:14 REPORTED :04/03/2024 11:25:55

CLINICAL INFORMATION:

UID:12385677 REQNO-1669336

CORP-OPD


BILLNO-1002124OPCS003255 BILLNO-1002124OPCS003255

Test Report Status

<u>Final</u>

Results

Biological Reference Interval Units



Ms. Hardeep Kaur, M.Sc. **Biochemistry**

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159

Meenahah: Malhotra

Dr. Ritu Pankaj (MD, Pathology), **PDCC**

Additional Director, 30897







View Report

Page 14 Of 21



CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -

L85110DL1996PLC076704

Email: lab.mohali@fortishealthcare.com



Ritu Pantay





CODE/NAME & ADDRESS : C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XB029400 PATIENT ID : FH.12385677 CLIENT PATIENT ID: UID:12385677

ABHA NO

AGE/SEX : 54 Years Male :29/02/2024 10:20:00 DRAWN RECEIVED: 29/02/2024 14:37:14

REPORTED :04/03/2024 11:25:55

CLINICAL INFORMATION:

UID:12385677 REQNO-1669336

CORP-OPD


BILLNO-1002124OPCS003255 BILLNO-1002124OPCS003255

Test Report Status

<u>Final</u>

Results

Biological Reference Interval Units



Ms. Hardeep Kaur, M.Sc. **Biochemistry**

Meenaheh: Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159

Ritu Pantay

Dr. Ritu Pankaj (MD, Pathology), **PDCC** Additional Director, 30897







CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -

Email: lab.mohali@fortishealthcare.com



L85110DL1996PLC076704

Page 15 Of 21





CODE/NAME & ADDRESS : C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XB029400 PATIENT ID : FH.12385677

CLIENT PATIENT ID: UID:12385677 ABHA NO

AGE/SEX : 54 Years

DRAWN

Male :29/02/2024 10:20:00 RECEIVED: 29/02/2024 14:37:14

REPORTED :04/03/2024 11:25:55

CLINICAL INFORMATION:

UID:12385677 REQNO-1669336

CORP-OPD


BILLNO-1002124OPCS003255 BILLNO-1002124OPCS003255

Test Report Status

<u>Final</u>

Results

Biological Reference Interval Units



Interpretation(s)

Ms. Hardeep Kaur, M.Sc. **Biochemistry**

Meenahah: Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159

Ritu Pantay

Dr. Ritu Pankaj (MD, Pathology), **PDCC** Additional Director, 30897





Page 16 Of 21



CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -

L85110DL1996PLC076704 Email: lab.mohali@fortishealthcare.com







CODE/NAME & ADDRESS : C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XB029400 PATIENT ID : FH.12385677

CLIENT PATIENT ID: UID:12385677

ABHA NO

AGE/SEX : 54 Years Male :29/02/2024 10:20:00 DRAWN RECEIVED: 29/02/2024 14:37:14

REPORTED: 04/03/2024 11:25:55

CLINICAL INFORMATION:

UID:12385677 REQNO-1669336

CORP-OPD

BILLNO-1002124OPCS003255 BILLNO-1002124OPCS003255

Test Report Status Results **Biological Reference Interval** Units **Final**

CLINICAL PATH - URINALYSIS

URINALYSIS

PHYSICAL EXAMINATION, URINE

YELLOW

METHOD: MANUAL EXAMINATION

CLEAR APPEARANCE

METHOD: MANUAL EXAMINATION

CHEMICAL EXAMINATION, URINE

PH 6.5 4.7 - 7.5

METHOD: DOUBLE INDICATOR PRINCIPLE

1.003 - 1.035 SPECIFIC GRAVITY <=1.005

METHOD: REFLECTANCE PHOTOMETRY (IONIC CONCENTRATION)

PROTEIN NOT DETECTED NOT DETECTED

METHOD: REFLECTION PHOTOMETRY (PROTEIN ERROR INDICATOR)

GLUCOSE NOT DETECTED NOT DETECTED

METHOD: REFLECTANCE PHOTOMETRY (GLUCOSE OXIDASE METHOD)

KETONES NOT DETECTED NOT DETECTED

METHOD: REFLECTION PHOTOMETRY (NITROPRUSSIDE)

NOT DETECTED NOT DETECTED BI OOD

METHOD: REFLECTANCE PHOTOMETRY (BENZIDINE REACTION)

NOT DETECTED NOT DETECTED BILIRUBIN

METHOD: REFLECTANCE SPECTROPHOTOMETRY (DIAZO REACTION)

NORMAL NORMAL UROBILINOGEN

METHOD: REFLECTANCE PHOTOMETRY (EHRLICH'S REACTION)

NOT DETECTED NITRITE NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY (DIAZO REACTION)

MICROSCOPIC EXAMINATION, URINE

Dr. Shafira Garg (MD, Pathology)

Dr. Irneet Mundi (MD,DNB Pathology) Associate Consultant, 34080

Dr. Ritu Pankaj (MD, Pathology), **PDCC**

Additional Director, 30897





Page 17 Of 21

PERFORMED AT:

CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Mohali, 160062 Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -

L85110DL1996PLC076704

Attending Consultant, 47150







CODE/NAME & ADDRESS : C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817 ACCESSION NO: **0006XB029400**PATIENT ID: FH.12385677

CLIENT PATIENT ID: UID:12385677

ABHA NO :

AGE/SEX : 54 Years Male DRAWN : 29/02/2024 10:20:00

RECEIVED : 29/02/2024 14:37:14 REPORTED : 04/03/2024 11:25:55

CLINICAL INFORMATION:

UID:12385677 REQNO-1669336

CORP-OPD

BILLNO-10021240PCS003255 BILLNO-10021240PCS003255

Test Report Status <u>Final</u>	Results	Biological Reference I	nterval Units
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)	3-5	0-5	/HPF
EPITHELIAL CELLS	NOT DETECTED	0-5	/HPF
CASTS	NOT DETECTED		
CRYSTALS	NOT DETECTED		
BACTERIA METHOD: REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NOT DETECTED	
YEAST	NOT DETECTED	NOT DETECTED	

Interpretation(s)

Shafua

Dr. Shafira Garg (MD, Pathology) Attending Consultant,47150 Inest.

Dr. Irneet Mundi (MD,DNB Pathology) Associate Consultant, 34080 Ritu Pantay

Dr. Ritu Pankaj (MD,Pathology), PDCC Additional Director, 30897





Page 18 Of 21

View Details






CLINICAL LABORATORY
Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

L85110DL1996PLC076704









CODE/NAME & ADDRESS : C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XB029400

PATIENT ID : FH.12385677 CLIENT PATIENT ID: UID:12385677

ABHA NO

AGE/SEX : 54 Years Male :29/02/2024 10:20:00 DRAWN

RECEIVED: 29/02/2024 14:37:14 REPORTED :04/03/2024 11:25:55

CLINICAL INFORMATION:

UID:12385677 REQNO-1669336

CORP-OPD

BILLNO-1002124OPCS003255 BILLNO-1002124OPCS003255

Test Report Status Results Biological Reference Interval Units <u>Final</u>

	SPECIALISED CHEMISTRY - HORMONE							
THYROID PANEL, SERUM								
Т3	133.2	80.00 - 200.00	ng/dL					
METHOD: SANDWICH (ECLIA)								
T4	7.27	5.10 - 14.10	μg/dL					
METHOD: SANDWICH (ECLIA)								
TSH (ULTRASENSITIVE)	1.050	0.270 - 4.200	μIU/mL					
METHOD : SANDWICH (ECLIA)								

Interpretation(s)

Meenahahi Malhotra

Dr. Meenakshi Malhotra (MD, Pathology)

Senior Consultant, 48159

Ritu Pambay

Dr. Ritu Pankaj (MD,Pathology), PDCC Additional Director, 30897



Page 19 Of 21

View Report



Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -

Email: lab.mohali@fortishealthcare.com



L85110DL1996PLC076704







ng/mL

PATIENT NAME: RAMESH CHAND REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817 ACCESSION NO : **0006XB029400**

PATIENT ID : FH.12385677 CLIENT PATIENT ID: UID:12385677

ABHA NO :

AGE/SEX : 54 Years Male DRAWN : 29/02/2024 10:20:00

RECEIVED : 29/02/2024 14:37:14 REPORTED :04/03/2024 11:25:55

CLINICAL INFORMATION:

UID:12385677 REQNO-1669336

CORP-OPD

BILLNO-10021240PCS003255 BILLNO-10021240PCS003255

Test Report Status <u>Final</u> Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - TUMOR MARKER

PROSTATE SPECIFIC ANTIGEN, SERUM

PROSTATE SPECIFIC ANTIGEN 0.811 0.0 - 3.1

METHOD: SANDWICH (ECLIA)

Interpretation(s)

PROSTATE SPECIFIC ANTIGEN, SERUM-- PSA is detected in the male patients with normal, benign hyperplastic and malignant prostate tissue and in patients with prostatitis.
- PSA is not detected (or detected at very low levels) in the patients without prostate tissue (because of radical prostatectomy or cystoprostatectomy) and also in the female patients.

- It a suitable marker for monitoring of patients with Prostate Cancer and it is better to be used in conjunction with other diagnostic procedures.
- Serial PSA levels can help determine the success of prostatectomy and the need for further treatment, such as radiation, endocrine or chemotherapy and useful in detecting residual disease and early recurrence of tumor.
- Elevated levels of PSA can be also observed in the patients with non-malignant diseases like Prostatitis and Benign Prostatic Hyperplasia.
- Specimens for total PSA assay should be obtained before biopsy, prostatectomy or prostatic massage, since manipulation of the prostate gland may lead to elevated PSA (false positive) levels persisting up to 3 weeks.
- As per American urological guidelines, PSA screening is recommended for early detection of Prostate cancer above the age of 40 years. Following Age specific reference range can be used as a guide lines.
- Measurement of total PSA alone may not clearly distinguish between benign prostatic hyperplasia (BPH) from cancer, this is especially true for the total PSA values between 4-10 ng/mL.
- Total PSA values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous medical interpretations. Recommended follow up on same platform as patient result can vary due to differences in assay method and reagent specificity.

References-

- 1. Burtis CA, Ashwood ER, Bruns DE. Teitz textbook of clinical chemistry and Molecular Diagnostics. 4th edition.
- 2. Williamson MA, Snyder LM. Wallach's interpretation of diagnostic tests. 9th edition.

End Of Report
Please visit www.agilusdiagnostics.com for related Test Information for this accession



Dr. Ritu Pankaj (MD,Pathology), PDCC

Additional Director, 30897

And Rama

Dr. Anita Sharma (MD, Microbiology) Director, Lab Medicine, 27672





Page 20 Of 21

View Details

View Report



CLINICAL LABORATORY
Fortis Heart Institute & Multispeciality Hospital, Sector 62,Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -

L85110DL1996PLC076704
Email: lab.mohali@fortishealthcare.com







CODE/NAME & ADDRESS : C000045483 - FORTIS

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XB029400

PATIENT ID : FH.12385677 CLIENT PATIENT ID: UID:12385677

ABHA NO

AGE/SEX : 54 Years Male :29/02/2024 10:20:00 DRAWN

RECEIVED: 29/02/2024 14:37:14 REPORTED: 04/03/2024 11:25:55

CLINICAL INFORMATION:

UID:12385677 REQNO-1669336

CORP-OPD

BILLNO-1002124OPCS003255 BILLNO-1002124OPCS003255

Test Report Status

Final

Results

Biological Reference Interval Units

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Ritu Pantay

Dr. Ritu Pankaj (MD, Pathology), **PDCC**

Additional Director, 30897

Dr. Anita Sharma (MD, Microbiology) Director, Lab Medicine, 27672





Page 21 Of 21

View Report



Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -L85110DL1996PLC076704

